Purpose: to determine the correlations between the peripapillary rnfl measures obtained with optical coherence tomography (oct) and scanning laser polarimetry (gdx). Methods: 42 eyes underwent rnfl measure with oct an...Purpose: to determine the correlations between the peripapillary rnfl measures obtained with optical coherence tomography (oct) and scanning laser polarimetry (gdx). Methods: 42 eyes underwent rnfl measure with oct and gdx and visual field and were divided in two subgroups according to the presence of significant corneal artifact at the gdx. correlations were calculated展开更多
Dear Editor,The latest article in your journal,authored by Wu et al.(2024),1 high-lights an intriguing finding:an increase in retinal nerve fiber layer(RNFL)thickness among pregnant women compared to their non-pregnan...Dear Editor,The latest article in your journal,authored by Wu et al.(2024),1 high-lights an intriguing finding:an increase in retinal nerve fiber layer(RNFL)thickness among pregnant women compared to their non-pregnant coun-terparts.This observed thickening of the RNFL in pregnant women might be attributed to pregnancy-related vasodilatation.Moreover,it also raises the possibility of a subclinical involvement of the central nervous system(CNS)in their condition,particularly for women with preeclampsia.展开更多
Background: Thyroid Eye Disease (TED) is known to alter tissues of the orbital cavity, including the optic nerve. However, its effect on measured global Retinal Nerve Fiber Layer (gRNFL) is not well elucidated. This c...Background: Thyroid Eye Disease (TED) is known to alter tissues of the orbital cavity, including the optic nerve. However, its effect on measured global Retinal Nerve Fiber Layer (gRNFL) is not well elucidated. This case evaluates the effect of teprotumumab on gRNFL in a patient with moderate TED. Observations: A 60-year-old female with controlled ocular hypertension and moderate TED received 8 standard IV teprotumumab infusions. Comprehensive ocular evaluations were performed pre-, during-, and post-treatment. Bilateral gRNFL thickness decreased (10 m OD;12 m OS) at 4 months post-treatment start, persisting at 8 months, but recovered at 20 months. Conclusions and Importance: Teprotumumab treatment in patients with TED led to a transient bilateral decrease in gRNFL thickness, which was restored to baseline levels with no adverse events reported. Monitoring gRNFL changes in teprotumumab-treated patients is crucial as gRNFL thinning indicates retinal ganglion cell damage. Teprotumumabs ability to dampen the IGF-IR inflammatory cascade may have reduced retinal inflammation, leading to recovery.展开更多
文摘Purpose: to determine the correlations between the peripapillary rnfl measures obtained with optical coherence tomography (oct) and scanning laser polarimetry (gdx). Methods: 42 eyes underwent rnfl measure with oct and gdx and visual field and were divided in two subgroups according to the presence of significant corneal artifact at the gdx. correlations were calculated
文摘Dear Editor,The latest article in your journal,authored by Wu et al.(2024),1 high-lights an intriguing finding:an increase in retinal nerve fiber layer(RNFL)thickness among pregnant women compared to their non-pregnant coun-terparts.This observed thickening of the RNFL in pregnant women might be attributed to pregnancy-related vasodilatation.Moreover,it also raises the possibility of a subclinical involvement of the central nervous system(CNS)in their condition,particularly for women with preeclampsia.
文摘Background: Thyroid Eye Disease (TED) is known to alter tissues of the orbital cavity, including the optic nerve. However, its effect on measured global Retinal Nerve Fiber Layer (gRNFL) is not well elucidated. This case evaluates the effect of teprotumumab on gRNFL in a patient with moderate TED. Observations: A 60-year-old female with controlled ocular hypertension and moderate TED received 8 standard IV teprotumumab infusions. Comprehensive ocular evaluations were performed pre-, during-, and post-treatment. Bilateral gRNFL thickness decreased (10 m OD;12 m OS) at 4 months post-treatment start, persisting at 8 months, but recovered at 20 months. Conclusions and Importance: Teprotumumab treatment in patients with TED led to a transient bilateral decrease in gRNFL thickness, which was restored to baseline levels with no adverse events reported. Monitoring gRNFL changes in teprotumumab-treated patients is crucial as gRNFL thinning indicates retinal ganglion cell damage. Teprotumumabs ability to dampen the IGF-IR inflammatory cascade may have reduced retinal inflammation, leading to recovery.
